Page Content
2015
- Busse R, Panteli D, Henschke C (2015): Arzneimittelversorgung in der GKV und 15 anderen europäischen Gesundheitssystemen. Universitätsverlag der TU Berlin
- Henschel F, Redaelli M, Siegel M, Stock S (2015): Correlation of Incident Potentially Inappropriate Medication Prescriptions and Hospitalisation: An Analysis Based on the PRISCUS List
- Panteli D, Eckhardt H, Nolting A, Busse R, Kulig M (2015): From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries. Health Research Policy and Systems
2014
- Habicht T, Van Ginneken E. Alleviating high out –of-pocket spending on drugs: practical examples from Estonia. Eurohealth 2014; 20(2): 29-32. (ISSN 1356-1030)
- San Miguel L, Augustin U, Busse R, Knai C, Rubert G, Sihvo S, .. (2014): Recognition of pharmaceutical prescriptions across the European Union: A comparison of five Member States’ policies and practices. Health Policy 116(2-3): 206-213
- Stock S, Redaelli M, Simic D, Siegel M, Henschel F (2014): Risk factors for the prescription of potentially inappropriate medication (PIM) in the elderly. Wien klin Wochenschr 126:604-612 (DOI: 10.1007/s00508-014-0589-2).
2013
- Henschke C, Sundmacher L, Busse R (2013): Structural changes in the German pharmaceutical market: Price setting mechanisms based on the early benefit evaluation. Health Policy 109(3): 209-225 (DOI 10.1016/j.healthpol.2012.12.005)
- Rohova M, Dimova A, Mutafova E, Atanasova E, Koeva S, Van Ginneken E (2013): Balancing regulation and free markets: The Bulgarian pharmaceutical sector. Eurohealth 2013; 19(1): 33-36.
- San Miguel L, Baeten R, Remme R, Busse R, Gil J, Knai C, Mäkinen M, Rubert G, Mckee M (2013): Obstacles to the recognition of medical prescriptions issued in one EU country and presented in another. Eur J Public Health 23(6) (DOI 10.1093/eurpub/ckt071)
2011
- Mangiapane S, Busse R (2011): Prescription Prevalence and Continuing Medication Use for Secondary Prevention After Myocardial Infarction: the Reality of Care Revealed by Claims Data Analysis. Dtsch Arztebl Int 2011; 108(50): 856-62
- Ognyanova D, Zentner A, Busse R (2011): Pharmaceutical reform 2010 in Germany: striking a balance between innovation and affordability. Eurohealth 17(1): 11-13
- Zentner A, Busse R (2011): Bewertung von Arzneimitteln – wie gehen andere Länder vor? G+G Wissenschaft 11(1): 25-34
2007
- Behrend C, Felder S, Busse R (2007): Susceptibility to Strategy of the Drug Component of the IPHCC+RxGroups Classification System in a Risk-Adjusted Morbidity Compensation Scheme - A Conceptional and Data-Supported Analysis. Gesundheitswesen 69(1): 1-10
- Mangiapane S, Blettner M, Schlattmann P (2007): Aspirin use and breast cancer risk: a meta-analysis and meta-regression of observational studies from 2001 to 2005. Pharmacoedidemiology and Drug Safety
2005
- Busse R, Schreyögg J, Henke K-D (2005): Pharmaceutical Regulation in Germany: improving efficiency and controlling expenditures. International Journal of Health Planning and Management 20(4): 329-349
- Gericke CA, Riesberg A, Busse R (2005): Ethical issues in funding orphan drug research and development. J Med Ethics (31) S. 164-168
- Schreyögg J, Busse R (2005): Physician drug budgets in Germany: effects on prescription behaviour. Journal of Pharmaceutical Finance, Economics & Policy 14(3): 77-95
- Zentner A, Velasco Garrido M, Busse R (2005): Methoden zur vergleichenden Bewertung pharmazeutischer Produkte. Köln: DIMDI
2003
- Böger GI, Hoopmann M, Busse R, Budinger M, Welte T, Böger R (2003): Arzneimittelverordnungen bei koronarer Herzkrankheit: Werden die Therapieempfehlungen beachtet? Zeitschrift für Kardiologie 92(6): 466-475
- Dixon A, Riesberg A, Weinbrenner S, Saka O, Le Grand J, Busse R (2003). Complementary and alternative medicine in the UK and Germany: A synthesis of research and evidence on supply and demand. London, Berlin: Anglo-German Foundation
- Krauth C, Jalivand N, Welte T, Busse R (2003): Cystic Fibrosis: Cost of illness and considerations for the economic evaluation of potential therapies. Pharmacoeconomics 21(14): 1001-1024
- Velasco-Garrido M, Busse R (2003): Whose "wish bias"? Ann Oncol 2003;14:1154
Zusatzinformationen / Extras
Quick Access:
Schnellnavigation zur Seite über Nummerneingabe